Neural oscillations are sensitive to several drugs influencing brain activity; accordingly, biomarkers based on neural oscillations are emerging as secondary endpoints in clinical trials and in quantifying effects in pre-clinical studies.
Neural oscillations are sensitive to several drugs. These several drugs are influencing brain activity. Biomarkers based on neural oscillations are emerging as secondary endpoints in clinical trials and in quantifying effects in pre-clinical studies. This is accordingly.